HOME > July 29, 2025
Daily News
July 29, 2025
- Chugai Sees 20% of Workforce Apply for Internal Job Postings
July 29, 2025
- Stella to Seek Japan Approval for BNCT as Angiosarcoma Trial Hits Goal
July 29, 2025
- Deciphera’s TGCT Drug Gets Key EMA Backing: Ono
July 29, 2025
- Opdivo-Yervoy Combo Approved for 1st Line HCC in Taiwan
July 29, 2025
- Shionogi, Torii to Start Co-Promotion in September upon Takeover
July 29, 2025
- Krystal Biotech Snags Japan Nod for Vyjuvek as 1st Topical Gene Therapy
July 29, 2025
- OTC-Like Drugs Flagged as Key Agenda Item by CEFP Members
July 29, 2025
- Post-Marketing Oversight and Regulatory Reviews Must Work as One, Says New MHLW Safety Chief
July 29, 2025
- Astellas Employee Did Not Appeal, Prison Sentence Finalized in China
July 29, 2025
- Japan Panel Urges Consolidation of Cancer Surgery, Radiotherapy amid Shrinking Surgeon Workforce
July 29, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
